1
|
Cabrero-Antonino JR, Leyva-Pérez A, Corma A. Iron-Catalysed Markovnikov Hydrothiolation of Styrenes. Adv Synth Catal 2012. [DOI: 10.1002/adsc.201100731] [Citation(s) in RCA: 54] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
2
|
Barfoot CW, Brown P, Dabbs S, Davies DT, Hennessy AJ, Miles TJ, Pearson ND. The design of efficient and selective routes to pyridyl analogues of 2,3-dihydro-1,4-benzodioxin-6-carbaldehyde. Tetrahedron Lett 2010. [DOI: 10.1016/j.tetlet.2010.07.099] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
3
|
Bolognesi ML, Budriesi R, Cavalli A, Chiarini A, Gotti R, Leonardi A, Minarini A, Poggesi E, Recanatini M, Rosini M, Tumiatti V, Melchiorre C. WB 4101-related compounds. 2. Role of the ethylene chain separating amine and phenoxy units on the affinity for alpha(1)-adrenoreceptor subtypes and 5-HT(1A) receptors. J Med Chem 1999; 42:4214-24. [PMID: 10514291 DOI: 10.1021/jm991065j] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
WB 4101 (1)-related benzodioxanes were synthesized by replacing the ethylene chain separating the amine and the phenoxy units of 1 with a cyclopentanol moiety, a feature of 6, 7-dihydro-5-[[(cis-2-hydroxy-trans-3-phenoxycyclopentyl)amino]meth yl] -2-methylbenzo[b]thiophen-4(5H)-one that was reported to display an intriguing selectivity profile at alpha(1)-adrenoreceptors. This synthesis strategy led to 4 out of 16 possible stereoisomers, which were isolated in the case of (-)-3, (+)-3, (-)-4, and (+)-4 and whose absolute configuration was assigned using a chiral building block for the synthesis of (-)-3 starting from (+)-(2R)-2, 3-dihydro-1,4-benzodioxine-2-carboxylic acid ((+)-9) and (1S,2S, 5S)-2-amino-5-phenoxycyclopentan-1-ol ((+)-10). The aim of this project was to further investigate whether it is possible to differentiate between these compounds with respect to their affinity for alpha(1)-adrenoreceptor subtypes and the affinity for 5-HT(1A) receptors, as 1 binds with high affinity at both receptor systems. The biological profiles of reported compounds at alpha(1)-adrenoreceptor subtypes were assessed by functional experiments in isolated rat vas deferens (alpha(1A)), spleen (alpha(1B)), and aorta (alpha(1D)) and by binding assays in CHO and HeLa cells membranes expressing the human cloned alpha(1)-adrenoreceptor subtypes and 5-HT(1A) receptors, respectively. Furthermore, the functional activity of (-)-3, (+)-3, (-)-4, and (+)-4 toward 5-HT(1A) receptors was evaluated by determining the induced stimulation of [(35)S]GTPgammaS binding in cell membranes from HeLa cells transfected with human cloned 5-HT(1A) receptors. The configuration of the cyclopentane unit determined the affinity profile: a 1R configuration, as in (+)-3 and (-)-4, conferred higher affinity at alpha(1)-adrenoreceptors, whereas a 1S configuration, as in (-)-3 and (+)-4, produced higher affinity for 5-HT(1A) receptors. For the enantiomers (+)-4 and (-)-4 also a remarkable selectivity was achieved. Functionally, the stereoisomers displayed a similar alpha(1)-selectivity profile, that is alpha(1D) > alpha(1B) > alpha(1A), which is different from that exhibited by the reference compound 1. The epimers (-)-3 and (+)-4 proved to be agonists at the 5-HT(1A) receptors, with a potency comparable to that of 5-hydroxytryptamine.
Collapse
MESH Headings
- Adrenergic alpha-Agonists/chemical synthesis
- Adrenergic alpha-Agonists/chemistry
- Adrenergic alpha-Agonists/metabolism
- Adrenergic alpha-Agonists/pharmacology
- Adrenergic alpha-Antagonists/chemical synthesis
- Adrenergic alpha-Antagonists/chemistry
- Adrenergic alpha-Antagonists/metabolism
- Adrenergic alpha-Antagonists/pharmacology
- Animals
- Aorta, Thoracic/drug effects
- CHO Cells
- Cloning, Molecular
- Cricetinae
- Dioxanes/chemical synthesis
- Dioxanes/chemistry
- Dioxanes/metabolism
- Dioxanes/pharmacology
- HeLa Cells
- Humans
- In Vitro Techniques
- Male
- Muscle Contraction/drug effects
- Muscle, Smooth/drug effects
- Radioligand Assay
- Rats
- Rats, Sprague-Dawley
- Receptors, Adrenergic, alpha-1/drug effects
- Receptors, Adrenergic, alpha-1/metabolism
- Receptors, Serotonin/drug effects
- Receptors, Serotonin/metabolism
- Receptors, Serotonin, 5-HT1
- Serotonin Antagonists/chemical synthesis
- Serotonin Antagonists/chemistry
- Serotonin Antagonists/metabolism
- Serotonin Antagonists/pharmacology
- Serotonin Receptor Agonists/chemical synthesis
- Serotonin Receptor Agonists/chemistry
- Serotonin Receptor Agonists/metabolism
- Serotonin Receptor Agonists/pharmacology
- Spleen/drug effects
- Stereoisomerism
- Structure-Activity Relationship
- Vas Deferens/drug effects
Collapse
Affiliation(s)
- M L Bolognesi
- Department of Pharmaceutical Sciences, University of Bologna, Via Belmeloro 6, 40126 Bologna, Italy
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Tvaermose-Nielsen O, Rachlin S, Dannacher H, Björkling F, Kirstein D, Bramm E, Nielsen CK, Mortensen JT, Binderup L. Discovery of OT4003, a novel, potent, and orally active cys-LT1 receptor antagonist. Bioorg Med Chem 1997; 5:415-27. [PMID: 9061206 DOI: 10.1016/s0968-0896(96)00253-2] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
The present paper describes the structural modifications leading to the discovery of a new series of quinoline-containing cys-LT1 receptor (LTD4 receptor) antagonists. A structural optimization with respect to the in vitro receptor binding, the in vivo brochoconstriction, and the toxicological effect in the form of peroxisomal proliferation was performed in order to achieve the target compound OT4003. OT4003 ((S)-(+)-E-2-(3-(2-(7- chloroquinolin-2-yl)ethenyl)phenylaminomethyl)-phenoxyl++ +-hexanoic acid) was found to be a potent and selective inhibitor of [3H]LTD4 specific binding to guinea pig lung membranes (IC50 2.4 +/- 1.0 nM), and also a potent, orally active, antagonist of LTD4 induced bronchoconstriction in guinea pigs [ED50 0.14 (ED16 0.1-ED84 0.4) mg/kg; 4 h pretreatment]. The enantiomerically pure OT4003 was prepared using a short convergent synthesis, including an enzymatic resolution step.
Collapse
|
5
|
Jackson WT, Fleisch JH. Development of novel anti-inflammatory agents: a pharmacologic perspective on leukotrienes and their receptors. PROGRESS IN DRUG RESEARCH. FORTSCHRITTE DER ARZNEIMITTELFORSCHUNG. PROGRES DES RECHERCHES PHARMACEUTIQUES 1996; 46:115-68. [PMID: 8754204 DOI: 10.1007/978-3-0348-8996-4_3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Affiliation(s)
- W T Jackson
- Lilly Research Laboratories, Eli Lilly & Company, Indianapolis, Indiana, USA
| | | |
Collapse
|
6
|
|
7
|
Hay DW, Muccitelli RM, Vickery-Clark LM, Novak LS, Osborn RR, Gleason JG, Yodis LA, Saverino CM, Eckardt RD, Sarau HM. Pharmacologic and pharmacokinetic profile of SK&F S-106203, a potent, orally active peptidoleukotriene receptor antagonist, in guinea-pig. PULMONARY PHARMACOLOGY 1991; 4:177-89. [PMID: 1668219 DOI: 10.1016/0952-0600(91)90009-r] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
In this report the pharmacologic and pharmacokinetic profile of the leukotriene receptor antagonist 3(S)-[(2-carboxyethyl)thio]-3-[2-(8-phenyloctyl)phenyl] propanoic acid (SK&F S-106203) in guinea-pigs is described. In isolated guinea-pig tracheae SK&F S-106203 was a potent, competitive antagonist of leukotriene (LT) D4-induced contractions (pA2 = 7.6). SK&F S-106203 was also a potent antagonist of LTE4-induced contractions (pKB = 7.3), but had little effect on those elicited by LTC4 (pKB = 5.5). SK&F S-106203 (10 microM) had no effect on contractions produced by histamine, carbachol, KCl, U-44069, PGF2 alpha or PGD2. In addition, SK&F S-106203 (10 microM) did not inhibit cyclic nucleotide phosphodiesterase (PDE) activity of several PDE isozymes. In guinea-pig lung membrane preparations, SK&F S-106203 was a potent antagonist of 3H-LTD4 binding with a Ki = 19.4 +/- 2.1 nM (n = 5). The pharmacokinetic profile of SK&F S-106203 was determined in unanesthetized guinea-pigs. Following an i.v. (bolus) dose (25 mg/kg), SK&F S-106203 disappeared from plasma in a biphasic fashion with half-lives of 0.1 h (50% of the area under the plasma concentration-time curve, AUC) and 11 h. The AUC obtained for SK&F S-106203 following i.v. administration was 87.3 +/- 7.5 micrograms-h/ml. Following an oral dose of SK&F S-106203 (100 mg/kg), the maximal plasma concentration (Cmax) and the time Cmax was achieved (Tmax) were 21.62 +/- 2.26 micrograms/ml and 4 +/- 1 h, respectively; the AUC was 279.9 +/- 41.8 micrograms-h/ml. Studies examining the effects of i.v. infusion of SK&F S-106203 revealed that marked inhibition of LTD4-induced bronchospasm was produced with steady-state plasma levels of SK&F S-106203 less than 1 microgram/ml (less than 2 microM). Oral (p.o.) pretreatment with 100 mumol/kg SK&F S-106203 for up to 24 h essentially abolished LTD4-induced bronchospasm; this correlated with sustained plasma concentrations of greater than 2 micrograms/ml. The results indicate that in guinea-pig airways, SK&F S-106203 is a potent and selective LT receptor antagonist that is active via aerosol, oral and i.v. routes of administration. When given orally, SK&F S-106203 is highly bioavailable and has a very long duration of action which correlates with the pharmacokinetic profile of the compound. SK&F S-106203 may be useful therapy in asthma and other disorders in which the LTs are thought to play a prominent pathophysiological role.
Collapse
Affiliation(s)
- D W Hay
- Department of Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406-0939
| | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Falcone RC, Orzechowski RF, Aharony D. Specific binding of 3H-ICI 198,615, a potent LTD4 antagonist, to guinea pig cardiac ventricular membranes. PROSTAGLANDINS 1990; 39:241-58. [PMID: 2160091 DOI: 10.1016/0090-6980(90)90044-v] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Peptido-leukotrienes (LTs) elicit myocardial depression in several mammalian species, and radioligand binding assays with 3H-LTC4 and 3H-LTD4 have provided evidence of putative receptor sites on guinea pig cardiac ventricular membranes (GPCVM). Our objective was to characterize specific binding of 3H-ICI 198,615, a potent and selective LTD4 antagonist, to the 155,000 X g pellet of GPCVM. 3H-ICI 198,615 (0.01-3.8 nM) showed high specific binding (85-90% of total), which was protein dependent, saturable (Bmax = 4914 +/- 706 fmol/mg protein, n = 3), of high affinity (Kd = 4.3 +/- 0.8 nM, n = 3) and without cooperativity. Equilibrium binding was achieved by 20 minutes and could be rapidly reversed by addition of excess unlabeled ICI 198,615 or FPL55712. Competition studies with 3H-ICI 198,615 against several LTD4 antagonists produced an order of potency: ICI 198,615 much greater than SKF102922 greater than FPL55712 greater than or equal to LY171883. Addition of divalent cations caused a concentration dependent decrease in specific binding apparently due to a reduction in affinity. Binding was not influenced by the guanine nucleotide analogs GTP gamma S and Gpp(NH)p, EDTA, or a multitude of diverse non-LT receptor agonists and antagonists. These data provide evidence supporting the existence of specific and high affinity binding sites for 3H-ICI 198,615 in GPCVM.
Collapse
Affiliation(s)
- R C Falcone
- Philadelphia College of Pharmacy and Science, Dept. of Pharmacology and Toxicology, PA 19104
| | | | | |
Collapse
|
9
|
Shu AYL, Richard Heys J, Mastrocola AR. Synthesis of tritiated leukotriene antagonist SK&F 104353. J Labelled Comp Radiopharm 1990. [DOI: 10.1002/jlcr.2580280213] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
10
|
Shu AYL, Villani AJ, Richard Heys J. Synthesis of carbon-14 labeled leukotriene antagonist SK&F 104353. J Labelled Comp Radiopharm 1990. [DOI: 10.1002/jlcr.2580280204] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
11
|
Gauthier J, Henien T, Lo L, Thérien M, Young R. A novel and efficient method for the preparation of asymmetric dithioacetals. Tetrahedron Lett 1988. [DOI: 10.1016/s0040-4039(00)82440-5] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
12
|
Thérien M, Gauthier J, Young R. Asymmetric dithioacetals II: A novel and versatile method for the preparation of chiral dithioacetals. Tetrahedron Lett 1988. [DOI: 10.1016/s0040-4039(00)82441-7] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
13
|
Sarau H, Mong S, Foley J, Wu H, Crooke S. Identification and characterization of leukotriene D4 receptors and signal transduction processes in rat basophilic leukemia cells. J Biol Chem 1987. [DOI: 10.1016/s0021-9258(18)61307-9] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
14
|
Musser JH, Kreft AF, Lewis AJ. New developments concerning leukotriene antagonists: a review. AGENTS AND ACTIONS 1986; 18:332-41. [PMID: 3529882 DOI: 10.1007/bf01964994] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
The numbers and subtypes of leukotriene (LT) receptors have only recently been investigated and more work is needed to evaluate the distribution of receptors on tissues and cells in both normal and pathological states. Classification of the heterogeneity of LT receptors may assist in the discovery of new antiallergy and antiinflammatory drugs much in the same way as the study of different adrenergic receptors has benefited cardiovascular drug discovery. The clinical evaluation of the currently available LT antagonists is awaited with interest; however, their therapeutic role in the treatment of asthma, a primary goal for the majority of these agents, will require painstaking clinical appraisal. They seem unlikely to supplant the currently used bronchodilators but may provide a valuable prophylactic adjunct that may suppress some of the inflammatory events that occur in obstructive lung disease. Whether the LT antagonists modify the hyperreactive state that prevails in asthma is also the subject of much speculation.
Collapse
|
15
|
Kuot GY, Dewey RH, Newton JF, Perchonock CD, McCarthy ME. Synthesis of 14C-labelled leukotriene receptor antagonists: 5-Substituted-4,6-dithianonanedioic acid derivatives. J Labelled Comp Radiopharm 1986. [DOI: 10.1002/jlcr.2580230608] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
16
|
Gleason JG, Perchonock CD, Torphy TJ. Chapter 8. Pulmonary and Antiallergy Agents. ANNUAL REPORTS IN MEDICINAL CHEMISTRY 1986. [DOI: 10.1016/s0065-7743(08)61118-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/12/2023]
|